Opportunity Information: Apply for PAR 08 245
Apply for PAR 08 245
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Apr 8, 2009 and posted on Dec 3, 2008.
- Applicants must submit their applications by Apr 8, 2009. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Public and State controlled institutions of higher education State governments Others (see text field entitled Additional Information on Eligibility for clarification) For profit organizations other than small businesses.
- Other Eligible Applicants include the following Eligible Agencies of the Federal Government Regional Organizations U.S. Territory or Possession Units of Local Governments Whereas Foreign institutions are not eligible to apply, they can be involved in Program Projects proposed by eligible Domestic institutions under subcontractual arrangements, if appropriate.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The grant opportunity titled "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)" (Funding Opportunity Number PAR-08-245) is a National Cancer Institute (NCI) Funding Opportunity Announcement designed to support coordinated, multi-project research programs focused on hepatocellular carcinoma (HCC), the most common form of primary liver cancer. The central goal is to advance the basic biology of HCC and translate that knowledge into meaningful strategies for prevention, improved diagnosis and prognosis, and better treatments that reduce illness and death in people affected by HCC. The FOA makes clear that proposals should be strongly grounded in mechanistic and experimental work rather than being purely descriptive or surveillance-oriented.
Scientifically, the FOA encourages applications that address several major areas. One core area is the etiology of HCC, including the underlying causal pathways and biologic mechanisms that lead to liver cancer development. This can include work aimed at understanding how liver injury and chronic disease states progress toward malignant transformation, or how molecular and cellular events initiate and drive HCC. A second emphasized area is the development of animal models for HCC, reflecting a need for experimental systems that faithfully reproduce important features of human disease and can be used to test hypotheses, prevention strategies, diagnostics, or therapies. The FOA also encourages novel approaches to preventing HCC malignancy, which could include interventions aimed at blocking progression from liver damage or pre-cancerous states to overt cancer, or identifying actionable prevention targets based on mechanistic findings.
In addition to prevention, the announcement places value on improved clinical tools, specifically the development of therapeutic or diagnostic tools that provide reliable prognostic indicators for HCC. In practical terms, this means biomarkers, assays, imaging-linked strategies, or other approaches that can more accurately predict outcomes such as risk of progression, recurrence, or treatment response. Finally, the FOA supports research that develops therapeutic approaches intended to minimize morbidity and mortality from HCC in humans, which can include innovative treatment strategies, new targets, combinations, or approaches to overcoming resistance, as long as the program remains centered on liver cancer biology and intervention. Across all these topics, the dominant expectation is that the proposed work is driven by liver cancer biology, prevention, and/or treatment rather than being focused solely on population-level epidemiology.
A key limitation spelled out in the FOA is that applications exclusively focused on population studies and epidemiology will not be supported. Population research can sometimes be part of a broader program, but the emphasis must remain on mechanistic, model-based, translational, and intervention-focused research tied to HCC biology. This reflects the NCI intent to fund programs that move beyond association studies and into causal understanding and actionable strategies.
In terms of funding structure, this opportunity uses the NIH Program Project Grant (P01) mechanism. A P01 is built around a unified research program made up of multiple interrelated projects that share a common central theme, objective, and scientific focus. Under this FOA, each application must include at least three component projects, meaning applicants need to assemble a collaborative program where each project is substantial on its own but also clearly strengthens and complements the others. The idea is to support teams that can tackle HCC from different angles (for example, mechanism, model development, prevention, and therapeutic translation) in a way that produces more impact than separate, uncoordinated projects.
The FOA is described as running in parallel with two related announcements of similar scientific scope that use different NIH mechanisms: PA-08-243 (R01) and PA-08-244 (R21). In practice, that means investigators with smaller or more exploratory efforts could consider those mechanisms, while PAR-08-245 is aimed at larger, integrated program project applications that require multi-project coordination.
Administrative details indicate that this is a discretionary grant opportunity within NIH, with activity categories spanning cancer cause and prevention, detection and diagnosis, treatment, and cancer biology (CFDA numbers 93.393, 93.394, 93.395, and 93.396). The FOA states there is no cost sharing or matching requirement, which is typical for many NIH research grants. Award decisions are contingent on the availability of funds and the receipt of a sufficient number of high-quality applications, meaning the NIH is not committing to a fixed number of awards in advance.
Eligibility is broad across many U.S.-based organizational types, including public and state-controlled institutions of higher education, private institutions of higher education, nonprofit organizations (including 501(c)(3) and non-501(c)(3) entities), small businesses, for-profit organizations other than small businesses, state governments, units of local government, U.S. territories or possessions, regional organizations, and eligible federal agencies. Foreign institutions are not eligible to apply as the primary applicant under this FOA, but they may participate through subcontracts under an eligible domestic applicant when appropriate, which allows international expertise or resources to be integrated into an otherwise U.S.-led program project.
The announcement was posted on December 3, 2008, with related record dates including a creation date of April 8, 2009, and an archive date of May 8, 2009. The listing includes an original closing date of May 31, 2011, but also notes a current closing date of April 8, 2009, reflecting the record status and archiving information associated with the opportunity listing. For full details, applicants were directed to the NIH Grants Guide page for PAR-08-245, with contact support through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
Overall, PAR-08-245 is aimed at funding integrated, multi-project HCC research programs that connect fundamental mechanisms to practical prevention, prognostic, diagnostic, and therapeutic advances. The program project format is meant to encourage coordinated collaboration across complementary projects so that progress in understanding HCC biology can more quickly inform model development and intervention strategies that reduce the burden of liver cancer.
Frequently Asked Questions (FAQs): Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01) (PAR-08-245)
What is the title of this grant opportunity?
The opportunity is titled "Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)".
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-08-245.
Which NIH institute is sponsoring this announcement?
This Funding Opportunity Announcement is from the National Cancer Institute (NCI).
What type of grant mechanism does this FOA use?
This FOA uses the NIH Program Project Grant (P01) mechanism.
What is a P01 Program Project Grant in the context of this FOA?
A P01 application is a coordinated, multi-project research program built around a unified theme and objective. Under this FOA, the expectation is that multiple interrelated projects work together in a way that creates more impact than separate, unconnected studies.
How many projects are required in a PAR-08-245 (P01) application?
Each application must include at least three component projects.
What disease area is the focus of this program project grant?
The program is focused on hepatocellular carcinoma (HCC), described as the most common form of primary liver cancer.
What is the central goal of PAR-08-245?
The central goal is to advance the basic biology of HCC and translate that knowledge into meaningful strategies for prevention, improved diagnosis and prognosis, and better treatments that reduce illness and death in people affected by HCC.
What kind of scientific approach does the FOA emphasize?
The FOA emphasizes proposals that are strongly grounded in mechanistic and experimental research, rather than work that is purely descriptive or surveillance-oriented.
What major research areas does the FOA encourage?
The FOA encourages research programs that address one or more of the following areas:
- Etiology of HCC: causal pathways and biologic mechanisms leading to liver cancer development.
- Animal model development: experimental systems that reproduce key features of human HCC and can be used to test hypotheses and interventions.
- Novel prevention approaches: interventions to block progression from liver injury or pre-cancerous states to malignancy, based on mechanistic findings.
- Prognostic and diagnostic tool development: reliable indicators of outcomes such as progression risk, recurrence, or treatment response (for example, biomarkers or assays).
- Therapeutic development: innovative strategies intended to reduce morbidity and mortality from HCC in humans, aligned with liver cancer biology and intervention.
What does the FOA mean by "etiology" of HCC?
In this FOA, etiology refers to the underlying causal pathways and biological mechanisms that lead to the development of HCC, including how liver injury and chronic disease states progress toward malignant transformation and what molecular/cellular events initiate and drive cancer.
Are animal model projects specifically encouraged?
Yes. The FOA explicitly emphasizes the development of animal models for HCC that faithfully reproduce important features of human disease and can be used to test hypotheses, prevention strategies, diagnostics, or therapies.
What kinds of prevention research are responsive to this FOA?
The FOA encourages novel prevention approaches aimed at blocking progression from liver damage or pre-cancerous states to overt cancer and identifying actionable prevention targets grounded in mechanistic findings.
What does the FOA say about diagnostic or prognostic tool development?
The FOA supports development of therapeutic or diagnostic tools that provide reliable prognostic indicators for HCC, such as methods that can better predict outcomes like progression, recurrence, or treatment response.
What kinds of treatment research does the FOA support?
The FOA supports research that develops therapeutic approaches intended to minimize morbidity and mortality from HCC in humans, including innovative strategies, new targets, combinations, or approaches to overcoming resistance, as long as the overall program remains centered on liver cancer biology and intervention.
Are purely descriptive studies considered responsive?
No. The FOA states that proposals should be mechanistic and experimental rather than being purely descriptive or surveillance-oriented.
Are population studies or epidemiology projects allowed?
The FOA states that applications exclusively focused on population studies and epidemiology will not be supported. Population research may be included only if it is part of a broader program where the main emphasis is mechanistic, model-based, translational, and intervention-focused research tied to HCC biology.
Can an application include some population-based work at all?
Potentially yes, but only when it supports a broader program where the dominant emphasis remains on mechanistic and intervention-oriented research connected to HCC biology, rather than an epidemiology-only focus.
How is this FOA related to other HCC funding announcements?
This FOA is described as running in parallel with two related announcements of similar scientific scope that use different NIH mechanisms: PA-08-243 (R01) and PA-08-244 (R21).
What is the difference between PAR-08-245 and the related R01/R21 announcements mentioned?
Based on the description provided, PAR-08-245 (P01) is intended for larger, integrated, multi-project program project applications, while PA-08-243 (R01) and PA-08-244 (R21) may be options for smaller or more exploratory efforts.
What activity categories are associated with this opportunity?
The activity categories span cancer cause and prevention, detection and diagnosis, treatment, and cancer biology.
What CFDA numbers are associated with this FOA?
The CFDA numbers listed are 93.393, 93.394, 93.395, and 93.396.
Is cost sharing or matching required?
No. The FOA states there is no cost sharing or matching requirement.
Are awards guaranteed under this FOA?
No. Award decisions are described as contingent on the availability of funds and the receipt of a sufficient number of high-quality applications, meaning the agency is not committing to a fixed number of awards in advance.
Who is eligible to apply?
Eligibility is broad across many U.S.-based organization types, including:
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Nonprofit organizations (including 501(c)(3) and non-501(c)(3))
- Small businesses
- For-profit organizations other than small businesses
- State governments
- Units of local government
- U.S. territories or possessions
- Regional organizations
- Eligible federal agencies
Can a foreign institution apply as the primary applicant?
No. Foreign institutions are not eligible to apply as the primary applicant under this FOA.
Can foreign collaborators participate in a PAR-08-245 project?
Yes. Foreign institutions may participate through subcontracts under an eligible domestic applicant when appropriate, allowing international expertise or resources to be included within a U.S.-led program project.
When was this FOA posted?
The announcement was posted on December 3, 2008.
What dates are associated with the record status for this opportunity?
The listing includes a creation date of April 8, 2009 and an archive date of May 8, 2009.
What is the closing date for this opportunity?
The listing notes an original closing date of May 31, 2011, and also a current closing date of April 8, 2009, reflecting the record status and archiving information associated with the opportunity listing.
Where are applicants directed for full details about PAR-08-245?
Applicants were directed to the NIH Grants Guide page for PAR-08-245 for full details.
Who should be contacted for access or linking issues?
The FOA references contact support through the NIH Office of Extramural Research (OER) webmaster for access or linking issues.
What is the overall intent of the NCI in offering this FOA?
The intent is to fund integrated, multi-project HCC research programs that connect fundamental mechanisms to practical advances in prevention, prognosis/diagnosis, and therapy, using the program project format to encourage coordinated collaboration across complementary projects.
Browse more opportunities from the same category: Education Health
Next opportunity: Biomedical Technology Research Resource (P41)
Previous opportunity: National Cooperative Drug Discovery and Development Groups (NCDDDG) for the Treatment of Mental Disorders, Drug or Alcohol Addiction (U01/U19)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 08 245
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 08 245) also looked into and applied for these:
| Funding Opportunity |
|---|
| Biomedical Technology Research Resource (P41) Apply for PAR 08 259 Funding Number: PAR 08 259 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Diversity promoting Institutions Drug Abuse Research Program (DIDARP) (R24) Apply for PAR 09 011 Funding Number: PAR 09 011 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Care Outcomes Research and Surveillance (CanCORS) Consortium (Limited Competition) U01 Apply for RFA CA 09 503 Funding Number: RFA CA 09 503 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Exploratory Centers for Translational Research on the Clinical Neurobiology of Drug Addiction (P20) Apply for RFA DA 09 012 Funding Number: RFA DA 09 012 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Research Education Grants for Statistical Training in the Genetics of Addiction (R25) Apply for PAR 08 081 Funding Number: PAR 08 081 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| SBIR Phase II Bridge Awards to Accelerate the Development of New Cancer Therapies and Cancer Imaging Technologies Toward Commercialization (SBIR R44) Apply for RFA CA 08 021 Funding Number: RFA CA 08 021 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR AREA for Health Disparities Research at Minority Serving Institutions (MSIs ) (R15) Apply for PA 08 171 Funding Number: PA 08 171 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Research Center of Excellence Grant Program (P50) Apply for PAR 08 046 Funding Number: PAR 08 046 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Core Center of Excellence Grant Program (P30) Apply for PAR 08 073 Funding Number: PAR 08 073 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Comprehensive Research Center of Excellence Grant Program (P60) Apply for PAR 08 086 Funding Number: PAR 08 086 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NINR Program Projects in Symptom Management Research and Program Projects in Health Promotion/Disease Prevention Research (P01) Apply for RFA NR 09 003 Funding Number: RFA NR 09 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NLM Grants for Scholarly Works in Biomedicine and Health (G13) Apply for PAR 09 030 Funding Number: PAR 09 030 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Nutrition and Diet in the Causation, Prevention, and Management of Heart Failure (R21) Apply for PA 06 136 Funding Number: PA 06 136 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Pilot Studies Oral Complications of Cancer Therapies (R21) Apply for PA 06 212 Funding Number: PA 06 212 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Clinical Trials Oral Complications of Cancer Therapy (R21) Apply for PAR 06 213 Funding Number: PAR 06 213 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Cutting Edge Basic Research Awards (CEBRA) (R21) Apply for PAR 06 209 Funding Number: PAR 06 209 Agency: National Institutes of Health Category: Education Health Funding Amount: $100,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R21) Apply for PA 06 224 Funding Number: PA 06 224 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Information Technologies and the Internet in Health Services and Intervention Delivery (R03) Apply for PA 06 225 Funding Number: PA 06 225 Agency: National Institutes of Health Category: Education Health Funding Amount: $50,000 |
| Mechanisms of Alcohol Associated Cancers (R21) Apply for PA 06 270 Funding Number: PA 06 270 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Exploratory Grants for Behavioral Research in Cancer Control (R21) Apply for PA 06 351 Funding Number: PA 06 351 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 08 245", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.